Factors influencing islet of Langerhans graft function and monitoring

Antonello Pileggi, Camillo Ricordi, Mario Alessiani, Luca A Inverardi

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Transplantation of islet of Langerhans represents a viable therapeutic option for insulin-dependent diabetes mellitus. Dramatic progress has been recently reported with the introduction of a glucocorticoid-free immunosuppressive regimen that improved success rate, namely, insulin independence for 1 year or more, from 8% to 100%. The fate of islet grafts is determined by many concurrent phenomena, some of which are common to organ grafts (i.e. rejection), while others are unique to nonvascularized cell transplants, including transplant cell mass and viability, as well as nonspecific inflammation at the site of implant. Moreover, islet grafts lack clinical markers of early rejection, making it difficult to recognize imminent rejection and to implement intervention with graft-saving immunosuppressive regimens. In the present review, we will address the problems influencing islet graft success and the monitoring of islet cell graft function.

Original languageEnglish
Pages (from-to)3-16
Number of pages14
JournalClinica Chimica Acta
Volume310
Issue number1
DOIs
StatePublished - Aug 20 2001

Fingerprint

Islets of Langerhans
Grafts
Transplants
Monitoring
Immunosuppressive Agents
Insulin
Transplantation (surgical)
Medical problems
Islets of Langerhans Transplantation
Glucocorticoids
Graft Rejection
Type 1 Diabetes Mellitus
Cell Survival
Biomarkers
Inflammation

Keywords

  • Autoimmunity
  • Graft function
  • Islets of Langerhans
  • Monitoring
  • Rejection
  • Transplantation

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry

Cite this

Factors influencing islet of Langerhans graft function and monitoring. / Pileggi, Antonello; Ricordi, Camillo; Alessiani, Mario; Inverardi, Luca A.

In: Clinica Chimica Acta, Vol. 310, No. 1, 20.08.2001, p. 3-16.

Research output: Contribution to journalArticle

Pileggi, Antonello ; Ricordi, Camillo ; Alessiani, Mario ; Inverardi, Luca A. / Factors influencing islet of Langerhans graft function and monitoring. In: Clinica Chimica Acta. 2001 ; Vol. 310, No. 1. pp. 3-16.
@article{49429b6aec2f4a9c9dfdce77966b0b61,
title = "Factors influencing islet of Langerhans graft function and monitoring",
abstract = "Transplantation of islet of Langerhans represents a viable therapeutic option for insulin-dependent diabetes mellitus. Dramatic progress has been recently reported with the introduction of a glucocorticoid-free immunosuppressive regimen that improved success rate, namely, insulin independence for 1 year or more, from 8{\%} to 100{\%}. The fate of islet grafts is determined by many concurrent phenomena, some of which are common to organ grafts (i.e. rejection), while others are unique to nonvascularized cell transplants, including transplant cell mass and viability, as well as nonspecific inflammation at the site of implant. Moreover, islet grafts lack clinical markers of early rejection, making it difficult to recognize imminent rejection and to implement intervention with graft-saving immunosuppressive regimens. In the present review, we will address the problems influencing islet graft success and the monitoring of islet cell graft function.",
keywords = "Autoimmunity, Graft function, Islets of Langerhans, Monitoring, Rejection, Transplantation",
author = "Antonello Pileggi and Camillo Ricordi and Mario Alessiani and Inverardi, {Luca A}",
year = "2001",
month = "8",
day = "20",
doi = "10.1016/S0009-8981(01)00503-4",
language = "English",
volume = "310",
pages = "3--16",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Factors influencing islet of Langerhans graft function and monitoring

AU - Pileggi, Antonello

AU - Ricordi, Camillo

AU - Alessiani, Mario

AU - Inverardi, Luca A

PY - 2001/8/20

Y1 - 2001/8/20

N2 - Transplantation of islet of Langerhans represents a viable therapeutic option for insulin-dependent diabetes mellitus. Dramatic progress has been recently reported with the introduction of a glucocorticoid-free immunosuppressive regimen that improved success rate, namely, insulin independence for 1 year or more, from 8% to 100%. The fate of islet grafts is determined by many concurrent phenomena, some of which are common to organ grafts (i.e. rejection), while others are unique to nonvascularized cell transplants, including transplant cell mass and viability, as well as nonspecific inflammation at the site of implant. Moreover, islet grafts lack clinical markers of early rejection, making it difficult to recognize imminent rejection and to implement intervention with graft-saving immunosuppressive regimens. In the present review, we will address the problems influencing islet graft success and the monitoring of islet cell graft function.

AB - Transplantation of islet of Langerhans represents a viable therapeutic option for insulin-dependent diabetes mellitus. Dramatic progress has been recently reported with the introduction of a glucocorticoid-free immunosuppressive regimen that improved success rate, namely, insulin independence for 1 year or more, from 8% to 100%. The fate of islet grafts is determined by many concurrent phenomena, some of which are common to organ grafts (i.e. rejection), while others are unique to nonvascularized cell transplants, including transplant cell mass and viability, as well as nonspecific inflammation at the site of implant. Moreover, islet grafts lack clinical markers of early rejection, making it difficult to recognize imminent rejection and to implement intervention with graft-saving immunosuppressive regimens. In the present review, we will address the problems influencing islet graft success and the monitoring of islet cell graft function.

KW - Autoimmunity

KW - Graft function

KW - Islets of Langerhans

KW - Monitoring

KW - Rejection

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=0034907589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034907589&partnerID=8YFLogxK

U2 - 10.1016/S0009-8981(01)00503-4

DO - 10.1016/S0009-8981(01)00503-4

M3 - Article

VL - 310

SP - 3

EP - 16

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 1

ER -